Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia

Although the BTK inhibitor ibrutinib has transformed the management of patients with CLL, it does not induce substantial apoptosis in vitro, and as such the mechanisms underlying its ability to kill CLL cells are not well understood. Acalabrutinib, a more specific BTK inhibitor now in development, a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Leukemia
Päätekijät: Deng, Jing, Isik, Elif, Fernandes, Stacey M., Brown, Jennifer R., Letai, Anthony, Davids, Matthew S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555835/
https://ncbi.nlm.nih.gov/pubmed/28111464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.32
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia